TC BioPharm (Holdings) plc EBIT

TC BioPharm (Holdings) plc (TCBP) currently reports a EBIT of $-24M as of June 2024. That compares with $-2.1M in the prior-year period — down 1054.2% year over year. That is above the sector sector average of $-63M. Use the charts on this page to explore TC BioPharm (Holdings) plc's EBIT history and peer comparisons.

TC BioPharm (Holdings) plc's EBIT decreased from $-2.1M to $-24M — a 1054.2% year-over-year decrease (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

TC BioPharm (Holdings) plc's EBIT of $-24M is higher than the its sector sector average of $-63M. That is roughly 60.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

TC BioPharm (Holdings) plc reported $-24M in EBIT as of June 2024. That compares with $-2.1M in the prior-year period — down 1054.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-24M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-63M. From there, open related valuation or income-statement pages for TC BioPharm (Holdings) plc, and consider following TCBP for alerts when major investors trade the stock.